Patents by Inventor Kenji Negoro
Kenji Negoro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11912679Abstract: [Problem] A compound which is useful as a STING inhibitor is provided. [Means for Solution] The present inventors have found aryl alkynamide derivatives having an inhibitory action on STING. The aryl alkynamide derivatives of the present invention have an inhibitory action on STING and can be used as an agent for treating an autoimmune disease, a neurodegenerative disease, a type I interferonopathy and/or other STING-mediated disease.Type: GrantFiled: September 26, 2023Date of Patent: February 27, 2024Assignees: Astellas Pharma, Inc., Mitobridge, Inc.Inventors: Junko Maeda, Ikumi Kuriwaki, Kai Kitamura, Yumi Yamashita, Kenichi Kakefuda, Akio Kamikawa, Kenji Negoro, Wataru Hamaguchi, Ryushi Seo, Jeffrey Ciavarri
-
Publication number: 20240018113Abstract: [Problem] A compound which is useful as a STING inhibitor is provided. [Means for Solution] The present inventors have found aryl alkynamide derivatives having an inhibitory action on STING. The aryl alkynamide derivatives of the present invention have an inhibitory action on STING and can be used as an agent for treating an autoimmune disease, a neurodegenerative disease, a type I interferonopathy and/or other STING-mediated disease.Type: ApplicationFiled: September 26, 2023Publication date: January 18, 2024Applicants: Astellas Pharma, Inc., Mitobridge, Inc.Inventors: Junko Maeda, Ikumi Kuriwaki, Kai Kitamura, Yumi Yamashita, Kenichi Kakefuda, Akio Kamikawa, Kenji Negoro, Wataru Hamaguchi, Ryushi Seo, Jeffrey Ciavarri
-
Patent number: 11646667Abstract: A current detection circuit capable of compensating for detection accuracy of a switching current through switching of a connection state of a resistor even when the switching current has a component in a direction opposite to a predetermined direction is provided. A current detection circuit for detecting a value of a component in a predetermined direction of a switching current using a current transformer, wherein, when the switching current flowing in a primary side of the current transformer has a component in a direction opposite to the predetermined direction, a connection state of reset elements on a secondary side of the current transformer is switched such that an impedance of a magnetic reset on the secondary side of the current transformer is decreased.Type: GrantFiled: September 28, 2021Date of Patent: May 9, 2023Assignee: TDK CORPORATIONInventors: Akinori Hariya, Kenji Negoro
-
Publication number: 20230107277Abstract: The present invention addresses the problem of providing a pharmaceutical composition, in particular a compound suitable for prevention and/or treatment of an inflammatory disease and/or a neurodegenerative disease. The inventors of the present invention conducted extensive studies to find a compound that has suppressive action on NLRP3 inflammasome activation, and found that a substituted pyridazine compound has suppressive action on NLRP3 inflammasome activation, leading to completion of the present invention. The substituted pyridazine compound according to the present invention is expected to serve as a drug for prevention and/or treatment of an inflammatory disease and/or a neurodegenerative disease.Type: ApplicationFiled: March 26, 2021Publication date: April 6, 2023Inventors: Yusuke Inagaki, Takashi Kamikubo, Takahiro Nigawara, Junko Maeda, Susumu Yamaki, Ikumi Kuriwaki, Maiko Iida, Junichi Shishikura, Yuka Koizumi, Kenji Negoro, Takanori Koike, Kengo Saba
-
Publication number: 20220103079Abstract: A current detection circuit capable of compensating for detection accuracy of a switching current through switching of a connection state of a resistor even when the switching current has a component in a direction opposite to a predetermined direction is provided. A current detection circuit for detecting a value of a component in a predetermined direction of a switching current using a current transformer, wherein, when the switching current flowing in a primary side of the current transformer has a component in a direction opposite to the predetermined direction, a connection state of reset elements on a secondary side of the current transformer is switched such that an impedance of a magnetic reset on the secondary side of the current transformer is decreased.Type: ApplicationFiled: September 28, 2021Publication date: March 31, 2022Applicant: TDK CORPORATIONInventors: Akinori HARIYA, Kenji NEGORO
-
Publication number: 20210090783Abstract: A coil structure includes a first winding portion and a second winding portion disposed so as to overlap each other with winding axes substantially parallel to each other. The first winding portion and the second winding portion have regions overlapping each other when viewed from a winding axis direction. The second winding portion has a rising portion extending in a cross section perpendicular to a direction of a current flowing through a conductor constituting the winding portion with a directional component away from the first winding portion included.Type: ApplicationFiled: September 16, 2020Publication date: March 25, 2021Applicant: TDK CORPORATIONInventors: Masanobu TABUCHI, Kenji NEGORO
-
Publication number: 20200313543Abstract: What is provided is a processing circuit capable of preventing a high voltage from being applied to a main circuit at the time of a sudden voltage change. A processing circuit includes a differentiation circuit configured to output a differential value of a change in a target voltage, a predetermined voltage output unit configured to output a predetermined voltage when the differential value output from the differentiation circuit is equal to or greater than a predetermined value, and a predetermined processing executor configured to execute predetermined processing based on a voltage output from the predetermined voltage output unit on a protection circuit having a function of performing protection on the basis of a current detected by a current detector.Type: ApplicationFiled: March 18, 2020Publication date: October 1, 2020Applicant: TDK CORPORATIONInventors: Akinori HARIYA, Kenji NEGORO
-
Patent number: 10781213Abstract: (?)-Jorumycin, ecteinascidin 743, saframycin A and related compounds, methods of preparing the same, formulations comprising the compounds, and methods of treating proliferative diseases with the same are provided.Type: GrantFiled: November 22, 2019Date of Patent: September 22, 2020Assignee: California Institute of TechnologyInventors: Brian M. Stoltz, Eric R. Welin, Scott C. Virgil, Pamela Tadross, Gerit M. Pototschnig, Aurapat (Fa) Ngamnithiporn, Kenji Negoro, Guillaume Lapointe, Max Klatte, Christopher Haley, Christian Gruenanger, Emil Glibstrup, Christopher Gilmore, Kevin McCormack Allan
-
Publication number: 20200157102Abstract: (?)-Jorumycin, ecteinascidin 743, saframycin A and related compounds, methods of preparing the same, formulations comprising the compounds, and methods of treating proliferative diseases with the same are provided.Type: ApplicationFiled: November 22, 2019Publication date: May 21, 2020Inventors: Brian M. Stoltz, Eric R. Welin, Scott C. Virgil, Pamela Tadross, Gerit M. Pototschnig, Aurapat (Fa) Ngamnithiporn, Kenji Negoro, Guillaume Lapointe, Max Klatte, Christopher Haley, Christian Gruenanger, Emil Glibstrup, Christopher Gilmore, Kevin McCormack Allan
-
Patent number: 10526334Abstract: (?)-Jorumycin, ecteinascidin 743, saframycin A and related compounds, methods of preparing the same, formulations comprising the compounds, and methods of treating proliferative diseases with the same are provided.Type: GrantFiled: July 18, 2018Date of Patent: January 7, 2020Assignee: California Institute of TechnologyInventors: Brian M. Stoltz, Eric R. Welin, Scott C. Virgil, Pamela Tadross, Gerit Maria Pototschnig, Aurapat (Fa) Ngamnithiporn, Kenji Negoro, Guillaume Lapointe, Max Klatte, Christopher Haley, Christian Gruenanger, Emil Glibstrup, Christopher Gilmore, Kevin McCormack Allan
-
Publication number: 20190048009Abstract: (?)-Jorumycin, ecteinascidin 743, saframycin A and related compounds, methods of preparing the same, formulations comprising the compounds, and methods of treating proliferative diseases with the same are provided.Type: ApplicationFiled: July 18, 2018Publication date: February 14, 2019Inventors: Brian M. Stoltz, Eric R. Welin, Scott C. Virgil, Pamela Tadross, Gerit Maria Pototschnig, Aurapat (Fa) Ngamnithiporn, Kenji Negoro, Guillaume Lapointe, Max Klatte, Christopher Haley, Christian Gruenanger, Emil Glibstrup, Christopher Gilmore, Kevin McCormack Allan
-
Patent number: 9951060Abstract: [Problem] To provide a compound which is useful as an active ingredient for a pharmaceutical composition for preventing or treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. [Means for Solution] The present inventors have found that a thiazole derivative substituted with pyrazinylcarbonylamino at the 2-position is an excellent muscarinic M3 receptor-positive allosteric modulator and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, thereby completing the present invention. 2-Acylaminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, for example voiding dysfunction such as underactive bladder.Type: GrantFiled: June 5, 2015Date of Patent: April 24, 2018Assignee: Astellas Pharma Inc.Inventors: Taisuke Takahashi, Takanori Koike, Kenji Negoro, Hiroaki Tanaka, Jun Maeda, Kazuhiro Yokoyama, Hajime Takamatsu
-
Patent number: 9844549Abstract: A compound which is useful as an active ingredient for a pharmaceutical composition for treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. The present inventors have found that a 2-aminothiazole derivative has an excellent muscarinic M3 receptor-positive allosteric modulator activity and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, thereby completing the present invention. 2-aminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, for example voiding dysfunction such as underactive bladder.Type: GrantFiled: August 25, 2015Date of Patent: December 19, 2017Assignee: Astellas Pharma Inc.Inventors: Taisuke Takahashi, Hiroaki Tanaka, Michinori Akaiwa, Kenji Negoro, Hisashi Mihara, Hideyoshi Fuji, Hajime Takamatsu
-
Publication number: 20170290824Abstract: A compound which is useful as an active ingredient for a pharmaceutical composition for treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. The present inventors have found that a 2-aminothiazole derivative has an excellent muscarinic M3 receptor-positive allosteric modulator activity and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, thereby completing the present invention. 2-aminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, for example voiding dysfunction such as underactive bladder.Type: ApplicationFiled: August 25, 2015Publication date: October 12, 2017Applicant: ASTELLAS PHARMA INC.Inventors: Taisuke TAKAHASHI, Hiroaki TANAKA, Michinori AKAIWA, Kenji NEGORO, Hisashi MIHARA, Hideyoshi FUJI, Hajime TAKAMATSU
-
Publication number: 20170197955Abstract: [Problem] To provide a compound which is useful as an active ingredient for a pharmaceutical composition for preventing or treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. [Means for Solution] The present inventors have found that a thiazole derivative substituted with pyrazinylcarbonylamino at the 2-position is an excellent muscarinic M3 receptor-positive allosteric modulator and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, thereby completing the present invention. 2-Acylaminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, for example voiding dysfunction such as underactive bladder.Type: ApplicationFiled: June 5, 2015Publication date: July 13, 2017Applicant: ASTELLAS PHARMA INC.Inventors: Taisuke TAKAHASHI, Takanori KOIKE, Kenji NEGORO, Hiroaki TANAKA, Jun MAEDA, Kazuhiro YOKOYAMA, Hajime TAKAMATSU
-
Patent number: 9562044Abstract: Thiazole derivatives having pyrazine-2-carbonylamino substituted at the 2-position of the following formula (I): are excellent muscarinic M3 receptor positive allosteric modulators, and are useful for treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M3 receptor. The 2-acylaminothiazole derivatives and salts thereof can be used for treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M3 receptor, for example, voiding dysfunctions such as underactive bladder.Type: GrantFiled: February 27, 2014Date of Patent: February 7, 2017Assignee: Astellas Pharma Inc.Inventors: Taisuke Takahashi, Jun Maeda, Yusuke Inagaki, Kenji Negoro, Hiroaki Tanaka, Kazuhiro Yokoyama, Hajime Takamatsu, Takanori Koike, Issei Tsukamoto
-
Publication number: 20160002218Abstract: [Problem] A compound which is useful as an active ingredient of a pharmaceutical composition for treating storage dysfunctions, voiding dysfunctions, and lower urinary tract diseases is provided. [Means for Solution] The present inventors have found that a thiazole derivative having pyrazine-2-carbonylamino substituted at the 2-position is an excellent muscarinic M3 receptor positive allosteric modulator, and is useful as an agent for preventing and/or treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M3 receptor, thereby completing the present invention. The 2-acylaminothiazole derivative or a salt thereof of the present invention can be used as an agent for preventing and/or treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M3 receptor, for example, voiding dysfunctions such as underactive bladder.Type: ApplicationFiled: February 27, 2014Publication date: January 7, 2016Applicant: Astellas Pharma Inc.Inventors: Taisuke TAKAHASHI, Jun MAEDA, Yusuke INAGAKI, Kenji NEGORO, Hiroaki TANAKA, Kazuhiro YOKOYAMA, Hajime TAKAMATSU, Takanori KOIKE, Issei TSUKAMOTO
-
Publication number: 20120035196Abstract: [Problem] The present invention has an object to provide a compound having a GPR40 agonistic activity, which is useful as a pharmaceutical composition, an insulin secretion promoter, or an agent for preventing/treating diabetes. [Means for Solution] The present inventors have extensively studied a compound having a GPR40 agonistic activity, and as a result, they have found that the compound (I) of the present invention or a pharmaceutically acceptable salt thereof, in which a carboxylic acid is bonded to a bicyclic or tricyclic moiety through methylene, and further, a benzene ring substituted with a monocyclic 6-membered aromatic ring is bonded to a bicyclic or tricyclic moiety through —O-methylene or —NH-methylene, has an excellent GPR40 agonistic activity. They have also found that the compound has an excellent insulin secretion promoting action and strongly inhibits increase in the blood glucose after glucose loading, thereby completing the present invention.Type: ApplicationFiled: April 21, 2010Publication date: February 9, 2012Inventors: Kenji Negoro, Kei Ohnuki, Yasuhiro Yonetoku, Kazuyuki Kuramoto, Yasuharu Urano, Hideyuki Watanabe
-
Patent number: 8022208Abstract: Problem: To provide compounds which have an anticoagulation effect based on their ability to inhibit the activated blood coagulation factor X and are useful as coagulation inhibitors or agents for prevention or treatment for diseases caused by thrombi or emboli. Means for Solution: Benzene derivatives or their salts having a characteristic chemical structure with a phenol ring and a benzene ring bonding to each other via an amide bond, in which the phenol ring further bonds to a benzene ring or a heteroaryl ring via an amide bond. They have an excellent effect of inhibiting the activated blood coagulation factor X, and especially have an excellent oral activity.Type: GrantFiled: November 7, 2006Date of Patent: September 20, 2011Assignee: Astellas Pharma Inc.Inventors: Fukushi Hirayama, Jiro Fujiyasu, Daisuke Kaga, Kenji Negoro, Daisuke Sasuga, Norio Seki, Ken-ichi Suzuki
-
Patent number: RE49111Abstract: [Problem] To provide a compound which is useful as an active ingredient for a pharmaceutical composition for preventing or treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. [Means for Solution] The present inventors have found that a thiazole derivative substituted with pyrazinylcarbonylamino at the 2-position is an excellent muscarinic M3 receptor-positive allosteric modulator and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, thereby completing the present invention. 2-Acylaminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, for example voiding dysfunction such as underactive bladder.Type: GrantFiled: April 23, 2020Date of Patent: June 21, 2022Assignee: ASTELLAS PHARMA INC.Inventors: Taisuke Takahashi, Takanori Koike, Kenji Negoro, Hiroaki Tanaka, Jun Maeda, Kazuhiro Yokoyama, Hajime Takamatsu